IRLAB Therapeutics AB (OSTO:IRLAB A) Tariff Resilience Score: 0/10 (As of Jul. 03, 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
36 GF Score
Price kr1.31
GF Value kr11.76
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Tariff Resilience Score?

IRLAB Therapeutics AB has the Tariff Resilience Score of 0, which implies that the company might have .

IRLAB Therapeutics AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes IRLAB Therapeutics AB might have .

IRLAB Therapeutics AB  (OSTO:IRLAB A) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

IRLAB Therapeutics AB Tariff Resilience Score Related Terms

OSTO:IRLAB A
36GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.31 is trading 88.8% below its estimated GF Value™ of kr11.76. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Tariff Resilience Score: 0
  • GF Value™: kr11.76 vs. price of kr1.31 (88.8% below fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score

Get the complete analysis for OSTO:IRLAB A

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.31
Price
kr11.76
GF Value